Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 20/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.63 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.63 |
| ▸ | CLK1 | P49759 | 1/20 | 0.63 |
| ▸ | CLK2 | P49760 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787858 | 0.94 | PIK3CG (0.65) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1789221 | 0.94 | PIK3CG (0.65) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1786677 | 0.93 | PIK3CG (0.70) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1784707 | 0.92 | PIK3CG (0.63) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1785414 | 0.92 | PIK3CG (0.61) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1784566 | 0.92 | PIK3CG (0.60) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL2256844 | 0.92 | PIK3CG (0.60) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL4032890 | 0.92 | PIK3CG (0.60) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1783539 | 0.91 | PIK3CG (0.66) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1787048 | 0.90 | PIK3CG (0.62) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998990-B2 | 5-phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2011-08-16 | — | — | US | disclosed |
| CN-101448801-B | 5-Phenyl-thiazol-2-yl-urea derivatives and their use as PI3 kinase inhibitors | NOVARTIS AG | 2011-06-15 | — | — | CN | disclosed |
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| CN-101448801-A | 5-Phenyl-thiazol-2-yl-urea derivatives and their use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2009-06-03 | — | — | CN | disclosed |
| EP-2029562-A1 | 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis Ag (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007134827-A1 | 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | CNKSR1, CDK8, MAPK8 | PIK3CG 98/4885PIK3CA 51/4885PIK3CD 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.